About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Clinicaltrials.gov identifier NCT03930498

Recruitment Status Recruiting

First Posted April 29, 2019

Last update posted March 19, 2020

Study Description

Brief summary:

This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.

  • Condition or Disease:Recurrent Nasopharyngeal Carcinoma
  • Intervention/Treatment: Drug: PD-1 blocking antibody
    Drug: Chemotherapy
    Radiation: IMRT
  • Phase: Phase 2
Detailed Description


Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 43 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial
  • Actual Study Start Date: March 2020
  • Estimated Primary Completion Date: November 2021
  • Estimated Study Completion Date: November 2022
Arms and interventions
Arm Intervention/treatment
Experimental: PD-1 antibody plus chemoradiotherapy
Drug: PD-1 blocking antibody
Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.

Drug: Chemotherapy
Cisplatin and Gemcitabine

Radiation: IMRT
IMRT 60-66Gy, 1.8-2.0Gy/f/day
Outcome Measures
  • Primary Outcome Measures: 1. Objective response rate [ Time Frame: After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days) ]
    Patient's short-term effect
  • Secondary Outcome Measures: 1. Disease control rate [ Time Frame: After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days) ]
    Patient's short-term effect
  • 2. Progression free survival [ Time Frame: 3 years ]
    From date of recruitment to disease progression
  • 3. Overall survival [ Time Frame: 3 years ]
    From date of recruitment to disease progression
  • 4. Adverse effects [ Time Frame: through study completion, an average of 3 months ]
    Evaluating with CTCAE v5.0
  • 5. Quality of life: EuroQoL 5 dimension [ Time Frame: through whole study, an average of 3 years ]
    Evaluating with questionnaire of EuroQoL 5 dimension, 5 level health state utility index (EQ-5D-5L)
Eligibility Criteria
  • Ages Eligible for Study: 18 to 65 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Inclusion Criteria:

- Diagnosed as local recurrence ± regional recurrence after ≥1 year of radical

- Not suitable for surgery;

- Newly histologic diagnosis of NPC (WHO II/III);

- Clinical stage rII-IVa (AJCC/UICC 8th);

- ECOG 0-1 point;

- PRANCIS score > 252 points;

- No treatment to rNPC, such as radiotherapy, chemotherapy, immunotherapy or biotherapy;

- No contraindications to immunotherapy or chemoradiotherapy;

- Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/L, HGB ≥ 90g/L,
PLT count ≥ 100×10E9/L;

- Adequate liver function: ALT/AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;

- Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥
60ml/min (Cockcroft-Gault formula);

- Take effective contraceptions during and two months after treatment;

- Patients must be informed of the investigational nature of this study and give written
informed consent.

Exclusion Criteria:

- Have recurrence with local necrosis;

- Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;

- Unexplained fever > 38.5 ℃, except for tumor fever;

- Treated with ≥ 5 days antibiotics one month before enrollment;

- Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,
nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy);

- Have a known history of human immunodeficiency virus (HIV), active Hepatitis B
(HBV-DNA ≥10E3copiers/ml) or hepatitis C virus (HCV) antibody positive;

- Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1

- Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial
-infarction within 1 year, or clinically meaningful arrhythmia that requires

- Have known allergy to large molecule protein products or any compound of study

- Pregnant or breastfeeding;

- Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical
cancer, and papillary thyroid carcinoma;

- Have received a live vaccine within 30 days of planned start of study therapy Has
psychiatric drug or substance abuse disorders that would interfere with cooperation
with the requirements of the trial;

- Any other condition, including mental illness or domestic/social factors, deemed by
the investigator to be likely to interfere with a patient's ability to sign informed
consent, cooperate and participate in the study, or interferes with the interpretation
of the results.

Contacts and Locations

Contact: Jingjing Miao, M.D 02087342638 miaojj1@sysucc.org.cn


China, Guangdong
Sun Yat-sen University Cancer Center

Sponsors and Collaborators

Sun Yat-sen University


Principal Investigator: Chong Zhao, M.D Sun Yat-sen University

More Information
  • Responsible Party: Sun Yat-sen University
  • ClinicalTrials.gov Identifier: NCT03930498 History of Changes
  • Other Study ID Numbers: High-risk rNPC-JS001
  • First Posted: April 29, 2019 Key Record Dates
  • Last Update Posted: March 19, 2020
  • Last Verified: March 2020
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Sun Yat-sen University: Adverse effects
    PD-1 antibody
    Intensity-modulated Radiation Therapy
  • Additional relevant MeSH terms: Nasopharyngeal Carcinoma Carcinoma